Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.
- Citation:
- Ann Oncol vol 23 (9) 2356-62
- Year:
- 2012
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- M S Czuczman J P Leonard S Jung J L Johnson E D Hsi J C Byrd B D Cheson
- Networks:
- Study
- CALGB-50402
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: